Sector News

Sanofi appoints Dr. Ameet Nathwani EVP, Group Chief Medical Officer

March 10, 2016
Life sciences

Sanofi announced the appointment of Dr. Ameet Nathwani as a new member of the Executive Committee, effective May 1, 2016.

Dr. Nathwani joins Sanofi from Novartis and will take the position of Executive Vice President, Group Chief Medical Officer.

Dr. Nathwani will be responsible for enterprise-wide medical, patient safety, medical quality assurance and will insure the highest standard of transparency and compliance in Sanofi’s interactions with healthcare providers, patients and medical organizations. He will work in cooperation with Global R&D and the Global Business Units. Dr. Nathwani succeeds Dr. Paul Chew who has served as Senior Vice President, Chief Medical Officer since January 2013 and plans to retire later this year.

“Our industry is experiencing increased pressure to support reimbursement with customized data from real-world evidence, demonstrate ongoing benefit-risk of registered products through continuous scientific data generation, and ensure that data are effectively and transparently communicated. In order to shape Sanofi’s strategy and enhance our world class medical capabilities to address these challenges we have elevated the role of the Chief Medical Officer to the Executive Committee,” said Olivier Brandicourt, Chief Executive Officer, Sanofi. ” We are very happy to count on Ameet’s strong experience in both development and medical fields. I would also like to take this opportunity to thank Paul Chew for his many valuable contributions to Sanofi. During his long-standing career, Paul has been a highly valued and key Sanofi leader who has demonstrated strong medical leadership.”

A U.K. citizen, born in Uganda and educated in the U.K., Dr. Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.

Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.

Source: Sanofi

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend